Formation of 1-beta-D-arabinofuranosylcytosine diphosphate choline in cultured human leukemic RPMI 6410 cells
- PMID: 274174
Formation of 1-beta-D-arabinofuranosylcytosine diphosphate choline in cultured human leukemic RPMI 6410 cells
Abstract
When incubated with 1-beta-D-arabinofuranosylcytosine (ara-C), RPMI 6410 cells formed a hitherto unrecognized ara-C metabolite, 1-beta-D-arabinofuranosylcytosine diphosphate choline. This compound was characterized by (a) chromatographic behavior, (b) chemical and enzymatic hydrolysis, (c) phosphorus content, and (d) incorporation of [5-3H]ara-C and [methyl-14C]choline. Formation of 1-beta-D-arabinofuranosylcytosine diphosphate choline by RPMI 6410 cells was enhanced in the presence of 3-deazauridine (DU) and was preceded by that of 1-beta-D-arabinofuranosylcytosine triphosphate. The antiproliferative effects of ara-C and DU toward RPMI 6410 cells were potentiated when the agents were present together. The anabolism of ara-C during a 24-hr interval of culture was markedly enhanced by the presence of DU; cellular concentrations of 1-beta-D-arabinofuranosylcytosine triphosphate and 1-beta-D-arabinofuranosylcytosine diphosphate choline were 5- and 15-fold higher than those in the absence of DU. This enhancement appears to be the basis of the potentiation of cytotoxicity resulting from combination of the agents. Pretreatment of RPMI 6410 cells with DU resulted in enhanced rates of cellular uptake of ara-C. ara-C uptake under these circumstances was blocked by the inhibitor of nucleoside transport, nitrobenzylthioinosine.
Similar articles
-
Formation of 1-beta-D-arabinofuranosylcytosine diphosphate choline in neoplastic and normal cells.Cancer Res. 1978 Jun;38(6):1730-3. Cancer Res. 1978. PMID: 274175
-
1-beta-D-arabinofuranosylcytosine-diphosphate-choline is formed by the reversal of cholinephosphotransferase and not via cytidylyltransferase.Cancer Res. 1992 Jul 15;52(14):3886-91. Cancer Res. 1992. PMID: 1377599
-
Potentiation of cytotoxicity of 1-beta-D-arabinofuranosylcytosine for K562 human leukemic cells by cadeguomycin.Cancer Res. 1987 Feb 1;47(3):713-7. Cancer Res. 1987. PMID: 3467840
-
Biochemical modulation of cytosine arabinoside.Pharmacol Ther. 1990;48(1):29-44. doi: 10.1016/0163-7258(90)90016-u. Pharmacol Ther. 1990. PMID: 2274576 Review.
-
The pharmacology of prodrugs of 5-fluorouracil and 1-beta-D-arabinofuranosylcytosine.Adv Pharmacol Chemother. 1984;20:21-67. doi: 10.1016/s1054-3589(08)60264-1. Adv Pharmacol Chemother. 1984. PMID: 6085531 Review. No abstract available.
Cited by
-
Cytosine arabinoside influx and nucleoside transport sites in acute leukemia.J Clin Invest. 1982 Feb;69(2):479-89. doi: 10.1172/jci110472. J Clin Invest. 1982. PMID: 6948829 Free PMC article.
-
Cytosine arabinoside in the treatment of acute myeloid leukemia: the role and place of high-dose regimens.Ann Hematol. 1991 Apr;62(4):119-28. doi: 10.1007/BF01702925. Ann Hematol. 1991. PMID: 2031974 Review.
-
Cytosine arabinoside transport and metabolism in acute leukemias and T cell lymphoblastic lymphoma.J Clin Invest. 1985 Feb;75(2):632-42. doi: 10.1172/JCI111741. J Clin Invest. 1985. PMID: 3871794 Free PMC article.
-
Oral cytarabine ocfosfate pharmacokinetics and assessment of leukocyte biomarkers in normal dogs.J Vet Intern Med. 2023 Nov-Dec;37(6):2429-2442. doi: 10.1111/jvim.16842. Epub 2023 Sep 5. J Vet Intern Med. 2023. PMID: 37670479 Free PMC article.
-
Effect of uracil arabinoside on metabolism and cytotoxicity of cytosine arabinoside in L5178Y murine leukemia.J Clin Invest. 1985 Jan;75(1):141-6. doi: 10.1172/JCI111666. J Clin Invest. 1985. PMID: 4038404 Free PMC article.